Erlotinib induced ectropion following papulopustular rash

doi:10.3315/jdcr.2015.1203

Contents

Abstract
Keywords

Download PDF pdf

Download XML

160 Views

67 Downloads

Share this article

Research Article | Volume 10 Issue 2 (None, 2016) | Pages 46 - 48

Erlotinib induced ectropion following papulopustular rash

Andac Salman

Eren Cerman

Dilek Seckin

Metin Kanitez

Under a Creative Commons license

Open Access

DOI : 10.3315/jdcr.2015.1203

PMID : PMC4517803

Received

April 5, 2015

Published

June 30, 2015

Abstract

Background:Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR).Main observations:A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy.Conclusions:EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.

Keywords

Adverse effects

Ectropion

Eye

Erlotinib

Papulopustular rash

Recommended Articles

Research Article

A Comparartive Study For The Role Of Color Doppler And Clinical Examination In The Management Of Varicose Vein

Anish Deepak Baxla,

...

Kumar Yogesh